Non-Allergic Eosinophilic Asthma

Mechanism of Action

FB918 is a fully-human antibody specifically targeting interleukin 33 (IL-33). It is discovered and screened from Oneness-owned antibody library and currently under pre-clinical development. FB918 regulates several cytokines signaling that induces asthma by inhibiting the binding of IL-33 to the ST2 receptor. According to literatures, IL-33 plays as a critical mediator in asthma and inflamed lung tissues. It is also a novel target bring promising future treatment as many global pharma companies are exploring its potential in different indications.

Current Status

FB918 is under pre-clinical development

Market Potential

The treatment of non-allergic eosinophilic asthma is still in unmet medical needs. The increase in the number of type 2 innate lymphocytes (ILC2) in such patients will cause the eosinophils to mature and migrate after being stimulated by IL-33 secreted from epithelial cells, leading to disease onset. According to market analysis reports, the market size of asthma was 18 billion USD and expects to reach 26 billion USD in 2027

R&D Progress
In Progress
Research Code Therapeutic Area Indication Pre-Clinical Phase I Phase II Phase III NDA Market More
  • FB918

    FB918 is a first-in-class antibody targeting the interleukin 33 (IL-33) for non-allergic eosinophilic asthma. It has been discovered and developed from Oneness-owned antibody library



要下載瀏覽器,請直接點擊以下: IE瀏覽器現已不支援大多數網站,並將於2022年6月終止服務

如何使用IE找到Microsoft Edge?

  1. 開啟新分頁(紅色框)
  2. 於搜尋框中打入Edge(紅色框),並按搜尋(藍色框)
  3. 點擊【立即啟動】(藍框處)打開 Microsoft Edge
    啟動Microsoft Edge